Assembly Biosciences, Inc. Stock

$18.75

2.91%

Nasdaq, Jul 11, 10:00 pm CET

ISIN

US0453961080

Symbol

ASMB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Assembly Biosciences, Inc. Stock price

$18.75

-257.25 93.21% 5Y

Nasdaq, Closing price Fri, Jul 11 2025

+0.53 2.91%

ISIN

US0453961080

Symbol

ASMB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$143.2m

Enterprise Value

$52.2m

Net debt

positive

Cash

$91.0m

Shares outstanding

7.6m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

4.5 | 5.0

EV/Sales

1.6 | 1.8

EV/FCF

negative

P/B

5.3

Financial Health

Equity Ratio

28.0%

Return on Equity

-120.4%

ROCE

-85.2%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$32.2m | $28.5m

EBITDA

$-44.5m | $-46.6m

EBIT

$-44.6m | $-44.7m

Net Income

$-39.9m | $-38.2m

Free Cash Flow

$-56.2m

Growth (TTM | estimate)

Revenue

148.3% | 0.0%

EBITDA

19.8% | -2.9%

EBIT

20.0% | 1.6%

Net Income

22.3% | 4.8%

Free Cash Flow

-304.1%

EPS

$-5.3

FCF per Share

$-7.4

Short interest

0.3%

Employees

Rev per Employee

$390.0k

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

Assembly Biosciences, Inc. Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a Assembly Biosciences, Inc. forecast:

7x Buy

78%

2x Hold

22%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a Assembly Biosciences, Inc. forecast:

Buy

78%

Hold

22%

Analyst Estimates with Stock Price Targets

Financial data from Assembly Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	32 32	148% 148% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	18 18	21% 21% 56%
- Research and Development Expense	59 59	27% 27% 183%
EBITDA	-45 -45	20% 20% -138%
- Depreciation and Amortization	0.13 0.13	64% 64% 0%
EBIT (Operating Income) EBIT	-45 -45	20% 20% -139%
Net Profit	-40 -40	22% 22% -124%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Assembly Biosciences, Inc. Stock News

Neutral

GlobeNewsWire

●

14 days ago

Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179

– Study will evaluate safety and antiviral activity of ABI-1179 in participants with recurrent genital herpes – – ABI-1179 IND cleared to support study expansion to sites in United States – – Phase 1b studies for ABI-1179 and ABI-5366 running concurrently with interim data for both candidates on track for fall 2025 – SOUTH SAN FRANCISCO, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Assembly Biosci...

Neutral

GlobeNewsWire

●

19 days ago

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

– Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be observed in final 400 mg cohort –

Neutral

GlobeNewsWire

●

about 2 months ago

Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that Jason Okazaki, chief executive officer and president, and Anuj Gaggar, MD, PhD, chief medical officer, will present in a fireside chat during the Jefferies 2025 Global Healthcare...

More Assembly Biosciences, Inc. News

Company Profile

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.

Head office	United States
CEO	Jason Okazaki
Employees	73
Founded	2005
Website	www.assemblybio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now